Synergistic seizure reduction in patient with persistently elevated N-desmethylclobazam levels, CYP450 genetic polymorphism, and responsive neurostimulator targeting centromedian nuclei of bilateral thalami

Clobazam (CLB) and cenobamate (CNB) are commonly used antiseizure medications (ASMs) in the treatment of patients with drug-resistant epilepsy (DRE). However, concomitant use of these two ASMs may lead to significant treatment-related adverse events (TRAE). Furthermore, these TRAE may be exacerbated...

詳細記述

書誌詳細

主要な著者:	Andrew Zillgitt, David E Burdette, Atheel Yako, Revati Rashingkar, Ashleigh Terrell, Sydney Jacobs, Michael D Staudt
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2025-09-01
シリーズ:	Epilepsy & Behavior Reports
主題:	Clobazam Cenobamate Pharmacogenetics Idiopathic generalized epilepsy Responsive neurostimulator
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2589986425000590
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!